Sandeep Kaur
Family · Bakersfield, CANPI 1316671902
Payments from drug & device makers
Across 121 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$502
- AstraZeneca$350
- GSK$272
- Lilly USA, LLC$137
- Otsuka America Pharmaceutical, Inc.$128
- Boehringer Ingelheim$115
- plus $354 from 10 others
What the payments were for
- Food & beverage$1,858100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 49 | $502 |
| AstraZeneca | 19 | $350 |
| GSK | 15 | $272 |
| Lilly USA, LLC | 8 | $137 |
| Otsuka America Pharmaceutical, Inc. | 6 | $128 |
| Boehringer Ingelheim | 6 | $115 |
| Pfizer | 3 | $52 |
| Novo Nordisk | 2 | $51 |
| Phathom Pharmaceuticals, Inc. | 3 | $51 |
| Irhythm Technologies, Inc. | 2 | $46 |
| Exact Sciences | 2 | $42 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 2 | $26 |
| Eisai Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $19 |
| Bayer | 1 | $16 |
How this compares
$1,858 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 84 | $95,681 |
| OzempicSemaglutide | 48 | $48,974 |
| JardianceEmpagliflozin | 29 | $37,088 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $28,133 |
| EliquisApixaban | 26 | $24,343 |
| XareltoRivaroxaban | 29 | $24,265 |
| TradjentaLinagliptin | 22 | $23,753 |
| MounjaroTirzepatide | 18 | $18,419 |
| GemtesaVibegron | 18 | $16,026 |
| FarxigaDapagliflozin Propanediol | 17 | $16,019 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $12,187 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,338 |
| CreonLipase/Protease/Amylase | 11 | $4,735 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $3,848 |
| Novolog FlexpenInsulin Aspart | 21 | $3,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $115 | $60,84251 claims |
| Novo NordiskOzempic | $51 | $48,97448 claims |
| PfizerEliquis | $52 | $24,34326 claims |
| Lilly USA, LLCMounjaro | $137 | $18,41918 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $27 | $16,02618 claims |
| AstraZenecaFarxiga | $350 | $16,01917 claims |
| GSKBreo Ellipta | $272 | $5,33814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.
Other family in Bakersfield
- Jennifer TougasBakersfield$302K
- Ashton ChaseBakersfield$86K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.